Top 10 sessions to attend at the AMCP Annual Meeting 2016

April 11, 2016

This year’s Academy of Managed Care Pharmacy (AMCP) Managed Care & Specialty Pharmacy Annual Meeting 2016, held April 19 to 22 in San Francisco, will feature several sessions of important to managed care professionals. Here are our top 10 recommendations.

 

 

 

 

 


This year’s Academy of Managed Care Pharmacy (AMCP) Managed Care & Specialty Pharmacy Annual Meeting 2016, held April 19 to 22 in San Francisco, will feature a wide array of sessions. To help you create a smart itinerary, Managed Healthcare Executive Editorial Advisor David Calabrese, vice president and chief pharmacy officer, OptumRx, has identified 10 must-attend sessions.

View our Events Calendar to plan ahead for more upcoming events.

 

 

NostaTechnology-supported medicine and its impact on specialty pharmacy

Tuesday, April 19

3:30 p.m. to 4:30 p.m.

Presented by John Nosta, president, NostaLab; and Mike A. Payne, chief commercial officer and head of medical affairs, Omada Health, Inc.

During this session, presenters will discuss how technology-supported medicine will impact specialty pharmacy in the next three years.

 

 

TharaldsonSpecialty pharmaceuticals in

Wednesday, April 20

8:45 a.m. to 10:00 a.m.

Presented by: Aimee Tharaldson, PharmD,
senior clinical consultant, emerging
therapeutics, Express Scripts, Inc.

During this session, Tharaldson will discuss how specialty medications are affecting managed care pharmacy. She will focus on new and emerging specialty medications and explore their likely role in therapy.

 

 

 

CardenFederal and state legislative and regulatory update

Wednesday, April 20

10:30 a.m. to 11:45 a.m.

Presented by: Reginia Grayson Benjamin, BS, JD,
director of legislative affairs,
Academy of Managed Care Pharmacy;
and Mary Jo Carden, RPh, JD, vice president,
government and pharmacy affairs,
Academy of Managed Care Pharmacy.

During this session, presenters will provide updates on the federal and state legislative and regulatory actions of interest to pharmacists and others in managed care and specialty pharmacy.

 

 

JhawarIntegrated, data-driven approaches to successful star ratings

Wednesday, April 20

12:45 p.m. to 2 p.m.

Presented by: Sharon K. Jhawar, PharmD, MBA, CGP,
corporate vice president of pharmacy,
Scan Health Plan;
and Rebecca Rabbitt, MS,
PharmD, vice president, government programs,
Medicare, Express Scripts

During this session, presenters will share best practices in designing data-driven strategies. They will share experience in implementing a pharmacy quality network pay-for-performance program to help improve member outcomes.

 

 

 

SchaferUpdate on safety and economic impact of biosimilars

Wednesday, April 20

12:45 p.m. to 2 p.m.

Presented by Jeremy A. Schafer, PharmD, MBA,
vice president, director specialty solutions,
Precision For Value

During this session, presenters will compare recent safety and economic data of biosimilars through case studies of select European countries and the early experience in the US. They will also provide an outlook for biosimilars in the United States.

 

 

Wednesday, April 20

2:30 p.m. to 3:45 p.m.

Presented by Jennifer T. Chang, PharmD, MPH,
supervisor of regional drug information services,
Kaiser Permanente

During this session, Chang will provide an overview of two tools released by ASCO and NCCN and how a managed care organization utilizes these tools in the formulary review process.

 

 

AveryPerspectives in assessing the value of emerging therapies

Wednesday, April 20

2:30 p.m. to 3:45 p.m.

Presented by Steven G. Avey, RPh, MS, FAMCP,
vice president specialty clinical team,
MedImpact Healthcare Systems, Inc.;
Diana Brixner, RPh, PhD, FAMCP, professor,
University of Utah;
Daniel C. Malone, RPh, PhD, professor,
University of Arizona;
and Brian Sweet, AstraZeneca Pharmaceuticals.

During this presentation, presenters will share three perspectives (payer, manufacturer, societal) on how emerging therapies should be valued.

 

 

 

BurgdorfStrategic management of high-cost generics: outcomes of a novel clinical program

Wednesday, April 20

2:30 p.m. to 3:45 p.m.

Presented by James R. Burgdorf, PhD,
health economist, MedImpact Healthcare
Systems, Inc., and Sara Erickson, PharmD,
health outcomes researcher, MedImpact

During this session, presenters will share a new approach that shifts utilization away from high-cost generics that have lower-cost alternatives.

 

LangUpdate on the electronic prior authorization landscape

 

Thursday, April 21

8:30 a.m. to 9:45 a.m.

Presented by James R. Lang, PharmD, MBA,
vice president of pharmacy services,
Blue Cross Blue Shield of Michigan;
and Tony Schueth, MS, CEO and managing partner,
Point-of-Care Partners, LLC.

 

 

During this session, presenters will provide an overview of the prior authorization and electronic prior authorization landscapes. They will also share how the industry is addressing key barriers.

 

 

 

DullToday's Medicaid program:  focus on pharmacy reimbursement trends

Friday, April 22

8 a.m. to 9:15 a.m.

Presented by Matthew Dull, BS,
vice president, government analytics,
Artia Solutions, LLC;
and George O. Kitchens, RPh, president,
Artia Solutions LLC.


During this presentation, presenters will provide the current landscape of Medicaid with an emphasis of recent trends such as statewide/universal preferred drug lists, prior authorizations, and 340B issues.